ReviewThe World Allergy Organization journal2026
Overview of allergic disease: Anaphylaxis - WAO White Book on Allergy 2026 - 2.11.
Review in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age-related differences in pediatric anaphylaxis: a single-center experience.BMC pediatrics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaphylaxis is a rapid-onset, potentially fatal systemic hypersensitivity reaction marked by airway, breathing, or circulatory compromise, which may occur even without skin symptoms. It is driven primarily by mast-cell activation-usually through IgE-mediated pathways-leading to the release of mediators such as tryptase and histamine. Basophils can also contribute. Although traditionally considered rare, anaphylaxis has a lifetime prevalence of 0.3-5.1%, with incidence rising globally in both adults and children, likely due to increased allergic diseases. Fatalities remain relatively low. Common triggers vary by age and geography: foods such as milk, peanuts, and tree nuts dominate in children; medications-especially beta-lactam antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs)-are more common in adults; and insect venoms are major causes in some regions. Diagnosis is clinical, based on rapid multisystem involvement, despite sometimes isolated cardiovascular or non-inhaled respiratory symptoms may occur. First measures should be to remove the allergen if possible and position the patient appropriately. Immediate intramuscular epinephrine injected into the lateral thigh is the first-line treatment, with repeat dosing as needed. Intranasal epinephrine is emerging as a needle-free alternative. Adjunctive measures include oxygen, intravenous fluids, and bronchodilators for bronchospasm. Antihistamines and corticosteroids may alleviate some symptoms but do not reverse anaphylaxis and must not delay epinephrine administration. Long-term management focuses on identifying triggers through detailed history, IgE testing, skin testing, or challenge procedures; however, up to 10% of cases remain idiopathic. Patients require action plans and access to self-administered epinephrine, though availability is limited in many regions. Key unmet needs include global device access, harmonized definitions and severity scoring, improved education, digital health integration, and deeper investigation into mechanisms, biomarkers, genetics, and cofactors to optimize diagnosis, prevention, and care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.